Drug Type Bispecific antibody, Biosimilar |
Synonyms Emicizumab Biosimilar (Wuhan YZY Biopharma Co., Ltd.), 艾美赛珠单抗生物类似药(武汉友芝友生物制药股份有限公司), Y225 |
Target |
Action inhibitors |
Mechanism F10 inhibitors(Coagulation factor X inhibitors), factor IXa inhibitors(Factor IXa inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hemophilia | Preclinical | China | 19 May 2024 |